Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA(R)
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand to Hold Third Quarter Results Conference Call on November 6
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Ligand to Hold Second Quarter Results Conference Call on July 31
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA
Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11
Ligand Pharmaceuticals Announces First Quarter Results
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
Ligand to Hold First Quarter Results Conference Call on May 1
Ligand Partner GlaxoSmithKline Receives FDA Acceptance and Granted Priority Review for PROMACTA(R) NDA
